Cannabinoids CB2 Receptors, One New Promising Drug Target for Chronic and Degenerative Pain Conditions in Equine Veterinary Patients.
Authors: Sánchez-Aparicio Pedro, Florán Benjamín, Rodríguez Velázquez Desiderio, Ibancovichi José Antonio, Varela Guerrero Jorge Antonio, Recillas Sergio
Journal: Journal of equine veterinary science
Summary
# Editorial Summary Osteoarticular disease in horses remains a significant clinical challenge, and whilst conventional treatment relies heavily on corticosteroids and NSAIDs, their chronic use carries substantial side-effect risks that limit therapeutic options for many patients. This review examines the pharmacological basis for cannabinoid CB2 receptor agonists as a novel analgesic approach, exploring how selective activation of CB2 receptors (distinct from the psychoactive CB1 pathway) modulates nociception without producing the unwanted central nervous system effects associated with cannabis use. The authors argue that synthetic CB2 agonists could offer meaningful pain relief in equine patients with chronic degenerative conditions such as osteoarthritis, particularly where individual patient factors or intolerance to conventional therapeutics prevent adequate analgesia through traditional routes. This represents a potentially valuable addition to the equine pain-management toolkit, though the review emphasises the need for further clinical investigation to establish efficacy, optimal dosing protocols, and safety profiles in the horse. For practitioners managing horses with refractory or treatment-limiting degenerative joint disease, understanding the mechanistic rationale behind cannabinoid CB2 receptor targeting provides important context for evaluating this emerging therapeutic avenue as regulatory frameworks evolve.
Read the full abstract on PubMed
Practical Takeaways
- •CB2 receptor agonists offer a potential pain management option for horses with chronic degenerative conditions like osteoarthritis when conventional NSAIDs and steroids are ineffective or contraindicated
- •Unlike CB1-activating cannabinoids, CB2-selective agonists avoid psychoactive side effects, making them safer for performance and therapeutic use in equine patients
- •This therapeutic avenue may address treatment-resistant pain in horses with individual sensitivities or contraindications to traditional anti-inflammatory medications
Key Findings
- •CB2 receptor agonists may provide antinociceptive properties without psychoactive side effects associated with CB1 activation
- •Synthetic cannabinoid type 2 receptor agonists represent a novel alternative to conventional steroid and NSAID therapies for equine chronic pain conditions
- •CB2 receptor activation modulates nociception through activation of cannabinoid receptor type 1 and type 2, with CB2 being selective for pain relief without behavioral effects